FREE

Section: Webinars Category: Wound Care

The Utilization of an Autologous Blood Clot Tissue Matrix in the Treatment of Chronic Wounds in Patients with Diabetes

Robert Snyder, DPM, MSc, MBA, CWSP

Robert Snyder, DPM, MSc, MBA, CWSP, discusses the epidemiology of diabetic foot. Dr Snyder also lists the differences between acute and chronic wound biochemistry, discusses the use and mechanism of action of autologous blood clot tissue wound matrix to accelerate wound healing.

Goals and Objectives
  1. Review the epidemiology of the diabetic foot
  2. List the differences between acute and chronic wound biochemistry and the extracellular matrix
  3. Review autologous blood clot tissue wound matrix (RD1) that has been shown to accelerate wound healing
  4. Review the mechanism of action (MOA) of topically applied blood clot tissue
  • Author
  • Robert Snyder, DPM, MSc, MBA, CWSP

    Dean, School of Podiatric Medicine
    Professor and Director of Clinical Research
    Director, Fellowship Program in Wound Care and Research
    Barry University School of Podiatric Medicine
    Miami, FL

  • System Requirements
  • To view Lectures online, the following specs are required:

    • PC Pentium-III class or better processor
    • 256MB minimum of RAM
    • Cable or DSL broadband Internet
    • Browsers must have javascript enabled. Most browsers have this feature enabled by default.
    • Adobe Acrobat Reader (Free) to print certificates
    • Supported Browsers:
      • Chrome
      • Firefox
      • IE 10+
      • Safari
      Supported Mobile OS:
      • Apple iOS 4.3+
      • Android 2.3+
      • Honeycomb 3.1+
      • Blackberry Playbook
  • Disclosure Information
  • It is the policy of PRESENT e-Learning Systems and it's accreditors to insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational programs. All faculty participating in any PRESENT e-Learning Systems sponsored programs are expected to disclose to the program audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts.

    ---

    Robert Snyder Has disclosed that he received Honorarium/Expenses from and is an advisor/consultant for Johnson & Johnson and Pfizer.